Omeros (OMER) Q2 2026 earnings review
YARTEMLEA Launch Ignites, Driving First Adjusted Profit Despite EU Roadblock
Omeros is undergoing a violent, positive financial transition. The U.S. launch of YARTEMLEA is a runaway success, with net sales surging 188% sequentially to $28.5M in its first full quarter. This hyper-growth triggered massive operating leverage, pushing Omeros to its first-ever positive adjusted net income ($1.8M) and positive operating cash flow ($4.1M). Management is aggressively weaponizing this cash, shrinking debt by buying back 2029 notes and retiring shares. The single major blemish is a negative CHMP opinion in Europe, stalling ex-U.S. expansion. Nevertheless, upcoming U.S. reimbursement catalysts (J-code, NTAP) suggest the domestic growth story is just beginning.
🐂 Bull Case
YARTEMLEA gross revenue hit $32.2M with stable gross-to-net margins (11.5%). The upcoming NTAP status (Oct 1) and new permanent J-Code (July 1) will further reduce friction for hospital adoption.
The company generated $4.1M in operating cash flow, proving the YARTEMLEA business model is highly lucrative and capable of funding the broader R&D pipeline without diluting shareholders.
🐻 Bear Case
The CHMP's negative opinion on narsoplimab's MAA is a severe blow. While management is requesting a re-examination, the timeline for European revenue has been indefinitely delayed.
GAAP net income dropped sequentially from $56.1M to $13.2M entirely due to wild non-cash mark-to-market swings on the 2029 notes' embedded derivatives, which obscures the underlying operational turnaround.
⚖️ Verdict: 🟢
Bullish. A negative EU regulatory opinion is painful, but the U.S. commercial execution is flawless. Reaching non-GAAP profitability and positive operating cash flow just months into launch is a rare and highly bullish signal for a biotech company.
Key Themes
YARTEMLEA U.S. Launch is Accelerating
U.S. execution is flawless. Gross sales hit $32.2M, up 190% from Q1's $11.1M. Crucially, gross-to-net (GTN) adjustments remained stable at 11.5% (vs 11.0% in Q1), proving Omeros isn't buying market share with deep discounts. The permanent J-code (effective July 1) and CMS New Technology Add-on Payment (effective Oct 1) are massive upcoming tailwinds that will streamline hospital billing and incentivize usage.
European Regulatory Rejection
Reversing the previously optimistic narrative, the EMA's CHMP adopted a negative opinion on the MAA for narsoplimab in TA-TMA. Management is pushing for a re-examination with an Ad Hoc Expert Group. This fundamentally breaks the timeline for ex-U.S. commercialization and forces the company to rely solely on the U.S. market to drive near-term cash flow.
Aggressive Capital Allocation
With the balance sheet fortified by the Q4 Novo deal and newly positive cash flow, management is playing offense. In July, they repurchased $30.5M of the 2029 Notes for $60.2M, cutting the outstanding principal to $40.3M and eliminating $8.6M in future interest. They also repurchased 0.5M shares in Q2 (0.8M YTD) at $11.70. This accelerating debt retirement fundamentally de-risks the equity.
GAAP Accounting Masks Core Performance
The accounting noise is deafening. Q2 GAAP net income was $13.2M, but this included an $11.5M non-cash gain from the 2029 Notes' embedded derivative. In Q1, GAAP net income was $56.1M driven by a $73.1M derivative gain. Investors must strip this out to see the real story: non-GAAP adjusted net income inflected from a $17.1M loss in Q1 to a $1.8M profit in Q2.
T-CAT Platform Validated by Science
Omeros' Targeted Complement Activating Therapy (T-CAT) platform, designed to bypass bacterial immune evasion to treat multi-drug resistant organisms (MDROs), was published in Science Translational Medicine. While early-stage, external peer-reviewed validation of this completely novel mechanism provides optionality to the pipeline.
Expanding the YARTEMLEA Franchise
Omeros is moving to expand narsoplimab beyond TA-TMA. Two investigator-sponsored studies will begin enrollment by year-end 2026: one for hyperinflammatory ARDS and another for prophylactic use in pediatric TA-TMA. This represents the next phase of TAM expansion for the commercial engine.
Other KPIs
Reversing from years of cash burn. Achieved in only the first full quarter of the YARTEMLEA launch. This proves the high-margin nature of the asset and establishes a floor for the company's valuation—Omeros is now self-sustaining.
Stable. Up only slightly from $26.7M in Q1. Generating an incremental $18.6M in net revenue on only $1.0M in incremental operating expense demonstrates staggering operating leverage.
Decelerating slightly from $136.3M in Q1 due to share repurchases ($5.7M in Q2). Post-quarter, Omeros deployed an additional $60.2M to repurchase debt, meaning actual pro-forma liquidity is closer to $70M, though now supported by positive operating cash flow.
Guidance
While management provided no specific numerical revenue guidance, these are massive structural catalysts. The permanent J-code simplifies outpatient/clinic billing, and the NTAP status provides eligible hospitals with additional Medicare reimbursement. Both act as accelerating forces for H2 2026 revenue.
Stable/Delayed. Previously targeted for early 2026, the NIDA-funded inpatient clinical trial for cocaine use disorder is now slated to start enrollment by year-end, following FDA requests for additional nonclinical data.
Stable. Management continues to guide for a Phase 1b launch next year, supported by recent successful nonhuman primate safety and efficacy data.
Key Questions
CHMP Re-examination Pathways
What specific data or trial design elements drove the CHMP's negative opinion on narsoplimab, and what historical precedent gives you confidence the Ad Hoc Expert Group will reverse this decision?
NTAP Revenue Impact
With NTAP status effective October 1, how much of a friction point was DRG reimbursement during Q1 and Q2, and what step-function increase in adoption do you model post-October?
Peak Operating Margins
You achieved profitability in Q2 with only $27.7M in OpEx against $28.5M in net sales. As YARTEMLEA scales, at what revenue run-rate do you expect to see the need for significant SG&A or R&D expansion, or does OpEx stay relatively flat from here?